The global oral proteins and peptides market, valued at US$7.35 billion in 2024, is projected to witness a robust CAGR of 22.1%, reaching US$8.85 billion in 2025 and soaring to US$24.00 billion by 2030. This growth is fueled by the increasing prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases, alongside growing patient preference for oral drug delivery and rapid advances in formulation technologies.
Among key innovations, semaglutide, a GLP-1 receptor agonist, has gained significant traction due to its proven efficacy in managing type 2 diabetes and obesity. Market growth is further supported by active R&D pipelines, including the development of new GLP-1 analogs by leading pharmaceutical companies.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=194705708
Segment Insights:
-
Molecule Type: The semaglutide segment leads the market in 2024, bolstered by rising diabetes incidence and high patient compliance with oral therapeutics. Other notable molecules include trofinetide, linaclotide, and voclosporin.
-
Formulation: Tablets are expected to be the fastest-growing segment, driven by benefits such as accurate dosing, extended shelf life, cost-effectiveness, and controlled release mechanisms that improve bioavailability.
-
Geography: Europe holds the second-largest regional market share, supported by favorable reimbursement policies, a strong regulatory landscape, and the presence of key industry players.
Leading Market Participants: The competitive landscape features global leaders including Novo Nordisk A/S, AbbVie Inc., Pfizer Inc., Aurinia Pharmaceuticals, Merck & Co., Inc., and others. Notably, Novo Nordisk has expanded its GLP-1 franchise significantly, increasing its global market share to 55.3% in Q1 2024, underpinned by strategic R&D investments exceeding USD 4.7 billion.
Strategic Outlook: As therapeutic needs evolve and the demand for non-invasive treatments intensifies, oral proteins and peptides represent a compelling growth frontier. Companies leveraging advanced delivery platforms and collaborative R&D models are poised to lead this transformation.
Key players in the oral proteins and peptides market include Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), SWK Holdings Corporation (US), AstraZeneca (UK), Regor Therapeutics Group (China), Viking Therapeutics (US), Protagonist Therapeutics Inc. (US), Rani Therapeutics Holdings, Inc. (US), Carmot Therapeutics, Inc. (US), Terns Pharmaceuticals, Inc. (US), Structure Therapeutics (US), Zealand Pharma (Denmark), Sciwind Biosciences (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China).
Novo Nordisk A/S (Denmark):
Novo Nordisk A/S is headquartered in Denmark and is a leading pharmaceutical company globally, particularly in the area of antidiabetic medications. With its extensive product portfolio, wide geographic presence, and well-established global brand, the company has successfully positioned itself as a market leader. Its focused research and manufacturing capabilities, especially regarding insulins and GLP-1 products—such as RYBELSUS—have played a significant role in its success. The company has increased its share of the global GLP-1 therapy market to 55.3% as of the first quarter of 2024, up from 50.8% in 2021. Last year, Novo Nordisk allocated USD 4.7 billion to research & development, which has strengthened its market position, largely due to its development of oral versions of existing drugs like semaglutide, which have significant potential applications.
AbbVie Inc. (US):
AbbVie Inc. holds the second position among US pharmaceutical companies specializing in oral proteins and peptides. The company offers oral peptides such as linaclotide and has focused intensively on other products like atogepant and Ubrogepant, positioning itself to capture a significant share of the market. Through its strategic emphasis on gastrointestinal diseases, AbbVie has successfully maintained its competitive edge, notably with linaclotide. Additionally, AbbVie has been proactive in forming strategic partnerships and collaborations to enhance its portfolio of oral proteins and peptides. These partnerships with biotech firms, academic institutions, and contract research organizations (CROs) allow the company to access cutting-edge technologies and innovative delivery methods, further expanding its presence in the market.
Pfizer Inc. (US):
Pfizer Inc. is one of the leading global health companies based in the US. The company entered the oral peptides market with NURTEC ODT, a CGRP receptor antagonist used to treat episodic migraines. Pfizer’s pipeline appears robust; one notable drug in development is Danuglipron, an oral GLP-1 receptor agonist currently in Phase II clinical trials. Pfizer also focuses on strategic business acquisitions to strengthen its portfolio. For instance, NURTEC ODT became part of Pfizer’s offerings by acquiring Biohaven Pharmaceutical in October 2022.
For more information, Inquire Now!
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/oral-proteins-peptides-market-194705708.html